Company Overview and News

3
Amazon sells Australians a way to beat geoblock with Prime

2018-06-18 reuters
SYDNEY (Reuters) - Amazon.com Inc began offering its paid subscription service in Australia on Tuesday, wooing premium users with a way around the geoblock on its offshore websites that has drawn criticism in the world’s 12th-biggest economy.
MYR MYGSF JBHHY MYRSY HVN JBH HNORY

3
Retail Food Group and AMP tumble out of key indices following share price collapses

2018-06-08 proactiveinvestors.com.au
The S&P Dow Jones Indices June quarterly rebalance is out, and as expected there has been a shake up in the composition after some well publicised underperformance, in particular from AMP, Retail Food Group and Myer.
AMC KDR GRNCY MYGSF MYRSY COH GNC AMP GRCLF AMCRY RFG CHEOY WHC MYR APX CLQ INCZY RFGPF CHEOF AAC IPL APT ICPVF AMP

3
Retail Food Group and AMP Ltd tumble out of key indices following share price collapses

2018-06-07 proactiveinvestors.com.au
The S&P Dow Jones Indices June quarterly rebalance is out, and as expected there has been a shake up in the composition after some well publicised underperformance, in particular from AMP, Retail Food Group and Myer.
AMC KDR GRNCY MYGSF MYRSY COH GNC AMP GRCLF AMCRY RFG CHEOY WHC MYR APX CLQ INCZY RFGPF CHEOF AAC IPL APT ICPVF AMP

3
Corporate Australia, Stop Blaming Women - Bloomberg

2018-05-17 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
NAUBF MYR WFAFY MYGSF MYRSY NAB NASXF AMP NABZY WFAFF

12
Case for gender diversity on boards will survive the post-AMP backlash

2018-05-12 theage.com.au
It was a sharply-worded question, read aloud almost two hours into the fractious and agonisingly drawn-out annual meeting of troubled wealth giant AMP.
MBL DSH FBU MGR MYGSF MYRSY FCREY MRVGF FRCEF OGFGY FSUGY MDBKY MYR MPL FSUMF FBU INCZY FMG OGFGF ICPVF IPL ORG

12
Case for gender diversity on boards will survive the post-AMP backlash

2018-05-12 smh.com.au
It was a sharply-worded question, read aloud almost two hours into the fractious and agonisingly drawn-out annual meeting of troubled wealth giant AMP.
MBL DSH FBU MGR MYGSF MYRSY FCREY MRVGF FRCEF OGFGY FSUGY MDBKY MYR MPL FSUMF FBU INCZY FMG OGFGF ICPVF IPL ORG

12
'The ship has sailed' - push back against on women on boards will fail

2018-05-11 theage.com.au
It was a sharply-worded question, read aloud almost two hours into the fractious and agonisingly drawn-out annual meeting of troubled wealth giant AMP.
MBL DSH FBU MGR MYGSF MYRSY FCREY MRVGF FRCEF OGFGY FSUGY MDBKY MYR MPL FSUMF FBU INCZY FMG OGFGF ICPVF IPL ORG

12
'The ship has sailed' - push back against on women on boards will fail

2018-05-11 smh.com.au
It was a sharply-worded question, read aloud almost two hours into the fractious and agonisingly drawn-out annual meeting of troubled wealth giant AMP.
MBL DSH FBU MGR MYGSF MYRSY FCREY MRVGF FRCEF OGFGY FSUGY MDBKY MYR MPL FSUMF FBU INCZY FMG OGFGF ICPVF IPL ORG

0
UPDATE 3-Australia's Myer swings to H1 loss, freezes dividend under e-commerce pressure

2018-03-21 reuters
SYDNEY (Reuters) - Top Australian department store chain Myer Holdings Ltd (MYR.AX) slumped to its biggest half-yearly loss since listing as it wrote off the value of its underperforming assets, conceding flawed execution of its strategy and an inadequate response to online competition.
MYR MYGSF MYRSY

0
UPDATE 1-Australia's Myer posts H1 loss on writedowns

2018-03-20 reuters
March 21 (Reuters) - Australia’s biggest department store chain Myer Holdings on Wednesday posted its worst half-year result since listing as it wrote down the value of its assets due to weak sales in its busiest period.
MYR MYGSF MYRSY

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to ASX:MYR / MYER HOLDINGS LIMITED on message board site Silicon Investor.

AMYRIS MYRY GRPN Killer?
Myriad Genetics, Inc. (MYGN) MYRY Myriad Interactive Media Inc.
Military Resale Group, Inc. (MYRG) HMYRQ - Heilig-Meyers Company